-
¡Bienvenidos a
Psiquiatría y Salud Integral!
Dr. Juan E. Mezzich y Dr. Miguel R. Jorge
-
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
By William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD
-
COMPLICATED CASE HISTORIES
Drug Induced Mania in a Boy with High Functioning Autism
By Mustafa Deniz Tutkunkardas, Nahit Motavalli Mukaddes
-
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
By Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP
-
Duloxetine for the Treatment of Major Depressive Disorder
By Charles B. Nemeroff, MD, PhD, Alan F. Schatzberg, MD, David J. Goldstein, MD, PhD, Michael J. Detke, MD, PhD, Craig Mallinckrodt, PhD, Yili Lu, PhD, and Pierre V. Tran, MD
-
ORIGINAL RESEARCHDuloxetine in Military Posttraumatic Stress Disorder
By Gerardo Villarreal, José M. Cañive, Lawrence A. Calais, Gregory Toney, Ashley K. Smith
-
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
-
Economic Impacts of Anxiety Disorders
By Ernst R. Berndt, PhD and Tamar Sisitsky, MA
-
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
-
EDITOR’S LETTER
Charles B. Nemeroff, MD, PhD
